# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001386570-25-000021
**Filing Date:** 2025-11
**Character Count:** 52340
**Document Hash:** 0cfcb4c02342b4bacb2b7f7ed5aaefe3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001386570-25-000021.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001386570-25-000021

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20251104

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Niagen Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37752
- **FILM NUMBER:** 251448821

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ChromaDex Corp.
- **DATE OF NAME CHANGE:** 20080624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

?xml version='1.0' encoding='ASCII'? cdxc-20251104

  

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 4, 2025**![NIAGEN-Bioscience-Logo-Horizontal.jpg](cdxc-20251104_g1.jpg)

**NIAGEN BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37752** | **26-2940963** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024**

(Address of principal executive offices, including zip code)

**(310) 388-6706**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | NAGE | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

------

**Item 2.02. Results of Operations and Financial Condition.**

On November 4, 2025, Niagen Bioscience, Inc. (the "Company") issued a press release announcing its earnings for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the "Securities Act") or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 7.01. Regulation FD Disclosure.**

On November 4, 2025, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.

The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| [99.1](ex991pressrelease-q32025.htm) | [Press Release dated](ex991pressrelease-q32025.htm)November 4, 2025 |
| [99.2](ex992earningspresentatio.htm) | [Earnings Presentation of Niagen Bioscience, Inc.](ex992earningspresentatio.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **NIAGEN BIOSCIENCE, INC.** | **NIAGEN BIOSCIENCE, INC.** |
| Dated: November 4, 2025 | By: | */s/ OZAN PAMIR* |
|  |  | Ozan Pamir |
|  |  | Chief Financial Officer |
|  |  | *(principal financial officer and duly authorized on behalf of the registrant)* |

---

## Exhibit 99.1

![niagen-biosciencexlogoxhora.jpg](niagen-biosciencexlogoxhora.jpg)

**Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook**

*Net sales increased 33% to $34.0 million* 

*Gross margin increased 100 bps to 64.5%* 

*Net income of $4.6 million, up $2.7 million from the prior year*

*Adjusted EBITDA increased by 120% to $6.4 million*

*Full year 2025 net sales outlook of 25% to 30% year-over-year growth*

**LOS ANGELES, CA - November 4, 2025 -** Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025.

**Third Quarter 2025 Financial Highlights Compared to Prior Year Period**

&nbsp;&nbsp;&nbsp;&nbsp;• Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%.

&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin increased 100 basis points to 64.5%.

&nbsp;&nbsp;&nbsp;&nbsp;• Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.

&nbsp;&nbsp;&nbsp;&nbsp;• Net income of $4.6 million or $0.06 earnings per share, up from $1.9 million or $0.02 earnings per share, in the prior year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA, a non-GAAP measure, increased 120% to $6.4 million.

&nbsp;&nbsp;&nbsp;&nbsp;• Total cash provided by operations of $12.8 million during the nine months ended September 30, 2025, ending the quarter with $64.3 million in cash.

&nbsp;&nbsp;&nbsp;&nbsp;• Full year 2025 outlook: Reaffirmed net sales growth expected between 25% to 30% (previously between 22% to 27%), driven by strong momentum in Tru Niagen® and Niagen® ingredients. Updated general and administrative and research and development expense outlook.

**Recent Operational Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;• In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging. The platform consolidates and curates peer-reviewed literature to make emerging science more accessible to consumers, clinicians, and researchers. This strategic initiative strengthens the Company's position as the scientific leader in NAD+ biology, enhances brand visibility, and expands digital infrastructure to support future commercialization and partnership opportunities.

&nbsp;&nbsp;&nbsp;&nbsp;• In September 2025, the Company was successful in a National Advertising Division challenge against another entity making false claims about their NAD+ products. The National Advertising Division found no human clinical evidence that the competitor's products elevate NAD+ levels in the body. The decision indicates the need for competent-and-reliable scientific evidence before advertisers make efficacy claims. This outcome reinforces the importance of rigorous scientific substantiation for claims in the NAD+ market and underscores the Company's commitment to evidence-based positioning.

&nbsp;&nbsp;&nbsp;&nbsp;• In October 2025, the Company expanded the nationwide distribution network for pharmaceutical-grade Niagen Plus™ IV and injectable therapies to more than 1,000 clinics, including over 50 iCRYO locations. This expansion represents continued progress in scaling the Company's clinical-grade NAD+ delivery network and broadening access for healthcare providers and wellness clinics offering NAD+-based boosting products for those seeking to improve cellular health and overall well-being.

"We delivered another strong performance with third quarter net sales of $34.0 million, up 33% year-over-year, and $4.6 million in net income," said Niagen Bioscience CEO, Rob Fried. "Our results reflected the continued execution across the business, with sustained sales growth, margin expansion, and disciplined cost management. The progress across both scientific leadership and commercial reach reinforces our confidence in the long-term fundamentals of our leadership in the NAD+ category."

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Results of operations for the three months ended September 30, 2025 compared to the prior year quarter** 

**Net Sales** for Niagen Bioscience increased 33%, or $8.4 million, to $34.0 million. The growth in net sales was primarily driven by growth in Tru Niagen® sales, supported by strong e-commerce channel performance, as well as modest growth in Niagen® ingredient sales reflecting stronger demand for food-grade Niagen®.

**Gross Margin** improved 100 bps to 64.5% primarily due to changes in product mix, the use of lower-cost inventory purchases, and improvements in labor and overhead utilization rates with higher sales.

**Operating Expense** increased 21%, or $3.1 million, to $17.7 million reflecting investments for business growth and brand awareness.

**•** Sales and marketing expense increased $1.7 million and improved by 170 basis points as a percentage of net sales to 25.8% of net sales, reflecting improved sales efficiency and disciplined investment. The increase in expenses primarily reflected higher investments to support brand growth in our consumer products segment.

**•** General and administrative expense increased $0.8 million, or 13%, primarily driven by higher employee-related expenses, share-based compensation, and professional and consulting fees.

• Research and development expenses increased $0.5 million due to higher professional and consulting fees, employee-related expenses and lab supply purchases.

**Net Income** was $4.6 million, or $0.06 per share, compared to $1.9 million, or $0.02 per share for the third quarter of 2024.

**Adjusted EBITDA,** a non-GAAP measure, was $6.4 million, up from $2.9 million for the third quarter of 2024. See "Reconciliation of Non-GAAP Financial Measures" for a reconciliation of non-GAAP Adjusted EBITDA to net income, the most directly comparable GAAP measure.

**Cash Flows from Operating Activities** had a net cash inflow of $12.8 million for the nine months ended September 30, 2025 compared to $3.5 million in the prior year. The approximately $9.3 million increase in cash provided by operating activities was primarily driven by improvements in net income, higher collections on trade receivables relative to the increase in trade receivables, higher share-based compensation expense, and an increase in accounts payable compared to a reduction in the prior year period. These increases were partially offset by a decrease in credit loss expense due to a recovery of previously written-off amounts and higher inventory purchases associated with scaling our inventory reserves.

**2025 Full Year Outlook**

For the full year, the Company reiterated its recently revised top-line guidance of 25% to 30% year-over-year net sales growth (up from 22% to 27% previously), reflecting continued E-Commerce momentum and new B2B partnerships. Gross margin is expected to improve year-over-year from 61.8% in 2024, driven by supply chain optimization, cost savings initiatives, and the benefit from lower-cost inventory sales. Sales and marketing expenses are projected to increase in absolute dollars compared to $29.5 million in 2024, but decrease as a percentage of net sales compared to 29.6% in 2024, reflecting targeted brand investment and greater marketing efficiency.

The Company is revising its outlook for both research and development, and general and administrative expenses. Research and development expenses are now expected to decrease as a percentage of net sales (previously expected to remain stable) compared to 6.0% in 2024, while continuing to increase in absolute dollars, consistent with prior expectations, and driven by project timing and study progress. General and administrative expenses are now expected to increase to approximately $8.0 to $9.0 million (previously $7.0 to $8.0 million) driven by higher share-based compensation, continued investments to support business growth, and the absence of a $3.5 million royalty expense reversal that occurred in 2024.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Investor Conference Call**

A live webcast will be held Tuesday, November 4, 2025 at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience's third-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investors Relations section of Niagen Bioscience's website at https://investors.niagenbioscience.com. The toll-free dial-in information for this call is 1-888-596-4144 with Conference ID: 8584242.

The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern Standard Time on November 4, 2025 through 11:59 p.m. Eastern Standard Time on November 11, 2025. The replay of the call can also be accessed by dialing 1-800-770-2030, using the Replay ID: 8584242.

**Important Note on Forward Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends" "estimates," "plans," "potential," "possible," "probable," "believes" "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience's Chief Executive Officer, statements related to the Company's 2025 financial outlook including but not limited to revenue growth, gross margin, expenses, investment plans, and the statements regarding Niagen Plus.

Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**About Niagen Bioscience, Inc.:**

Niagen Bioscience is a global bioscience company dedicated to healthy aging. The Niagen Bioscience team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. Niagen Bioscience is the innovator behind the NAD+ precursor nicotinamide riboside chloride ("NRC" commonly referred to as "NR"), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide riboside chloride and other NAD+ precursors are protected by Niagen Bioscience's patent portfolio.

The Company delivers Niagen® as the sole or principal dietary ingredient in its consumer product line Tru Niagen® available at www.TruNiagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Niagen®, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at www.NiagenBioscience.com to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company.

**Contacts:** 

---

| |
|:---|
| **Investor Relations** |
| ICR, LLC |
| Reed Anderson |
| 1 (626) 277-1260 |
| Stephanie Carrington |
| 1 (626) 277-1282 |
| <u>NiagenIR@ICRInc.com</u> |
| **Media Relations** |
| Kendall Knysch |
| Senior Director of Communications, Public Relations, & Partnerships |
| +1 (310) 388-6706 Ext. 689 |
| <u>Kendall.Knysch@NiagenBio.com</u> |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Statements of Operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| *(In thousands, except per share data)* |  |  |  |  |
| Sales, net | $**33986** | $25580 | $**95584** | $70472 |
| Cost of sales | **12058** | 9340 | **34099** | 27083 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | **21928** | 16240 | **61485** | 43389 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | **8768** | 7044 | **25092** | 20753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | **1795** | 1290 | **4620** | 4701 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | **7129** | 6304 | **19580** | 17320 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **17692** | 14638 | **49292** | 42774 |
| Operating income | **4236** | 1602 | **12193** | 615 |
| Nonoperating income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | **564** | 276 | **1575** | 756 |
| Income before provision for income taxes | **4800** | 1878 | **13768** | 1371 |
| Provision for income taxes | **222** |  | **518** |  |
| Net income | $**4578** | $1878 | $**13250** | $1371 |
| Net income per share attributable to common stockholders: |  |  |  |  |
| Basic | $**0.06** | $0.02 | $**0.17** | $0.02 |
| Diluted | $**0.05** | $0.02 | $**0.15** | $0.02 |
| Weighted average common shares outstanding: |  |  |  |  |
| Basic | **79779** | 75972 | **78953** | 75588 |
| Diluted | **86619** | 77768 | **85487** | 76804 |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| *(In thousands)* | **September 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents, including restricted cash of $152 for both periods presented | $**64290** | $44660 |
| &nbsp;&nbsp;Trade receivables, net of allowances of $137 and $95, respectively | **8506** | 7768 |
| &nbsp;&nbsp;Inventories | **18791** | 9192 |
| &nbsp;&nbsp;Prepaid expenses and other assets | **2029** | 2482 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **93616** | 64102 |
| Leasehold improvements and equipment, net | **1499** | 1719 |
| Intangible assets, net | **246** | 359 |
| Right-of-use assets | **2361** | 1730 |
| Other long-term assets | **417** | 368 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**98139** | $68278 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $**12742** | $8526 |
| &nbsp;&nbsp;Accrued expenses | **8700** | 7817 |
| &nbsp;&nbsp;Current maturities of operating lease obligations | **976** | 982 |
| &nbsp;&nbsp;Current maturities of finance lease obligations | **2** | 12 |
| &nbsp;&nbsp;Customer deposits | **292** | 611 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **22712** | 17948 |
| Deferred revenue | **2674** | 2579 |
| Operating lease obligations, less current maturities | **2077** | 1657 |
| Total stockholders' equity | **70676** | 46094 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $**98139** | $68278 |

---

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|<br>*(In thousands)* | **2025** | **2024** |
| **Net cash provided by / (used in):** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $**12825** | $3526 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing activities | **(191)** | (74) |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing activities | **6996** | 1621 |
| Net increase in cash and cash equivalents | **19630** | 5073 |
| Cash and cash equivalents beginning of period | **44660** | 27325 |
| Cash and cash equivalents at end of period | $**64290** | $32398 |

---

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

------

**Niagen Bioscience, Inc. and Subsidiaries**

**Unaudited Reconciliation of Non-GAAP Financial Measures**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** | **Reconciliation of Net Income to Adjusted EBITDA** |
| *(In thousands)* | **Q3 2025** | **Q2 2025** | **Q1 2025** | **Q4 2024** | **Q3 2024** |
| Net income, as reported | $**4578** | $3609 | $5063 | $7179 | $1878 |
| *Adjustments:* |  |  |  |  |  |
| &nbsp;&nbsp;Interest income, net | **(564)** | (552) | (459) | (373) | (276) |
| &nbsp;&nbsp;Provision for income taxes | **222** | 128 | 168 | 305 |  |
| &nbsp;&nbsp;Depreciation | **157** | 158 | 158 | 151 | 164 |
| &nbsp;&nbsp;Amortization of intangibles | **38** | 38 | 37 | 38 | 38 |
| &nbsp;&nbsp;Noncash lease expense | **164** | 159 | 173 | 169 | 164 |
| &nbsp;&nbsp;Share-based compensation | **1756** | 1488 | 1075 | 752 | 735 |
| &nbsp;&nbsp;Severance and restructuring | **10** | 21 | 4 | (4) | 185 |
| &nbsp;&nbsp;Reversal of previously accrued royalties and license maintenance fees (1) | **—** |  |  | (3521) |  |
| &nbsp;&nbsp;Recovery of credit losses related to legal settlement (2) | **—** |  | (1325) | (1325) |  |
| Adjusted EBITDA | $**6361** | $5049 | $4894 | $3371 | $2888 |

---

(1) The reversal of previously accrued royalties and license maintenance fees related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements.

(2) The recovery of credit losses relates to the 2024 legal settlement with Elysium Health, LLC, paid in two installments, reversing a bad debt write-off from 2019.

**Non-GAAP Financial Information:**

To supplement Niagen Bioscience's unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. Niagen Bioscience believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company's historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company's financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company's economic performance year-over-year.

Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including the reversal of previously accrued royalties and license maintenance fees, and the recovery of previously recognized credit losses from a legal settlement. While Niagen Bioscience believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company's GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.

Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company's non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP.

![niagen-biosciencexlogoxicona.jpg](niagen-biosciencexlogoxicona.jpg)

## Exhibit 99.2

![](ex992earningspresentatio001.jpg)

Niagen Bioscience, Inc. Earnings Presentation Third Quarter 2025 Nasdaq: NAGE \| November 4, 2025

------

![](ex992earningspresentatio002.jpg)

SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2025 financial outlook, and which may be identified by the use of words like "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows, planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we offer and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management's current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward- looking statements. These risks and uncertainties include those risk factors discussed in Part I, "Item 1A. Risk Factors" of our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities Exchange Commission (the "Commission"), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: our relationships with major customers; our ability to maintain or develop our sales, marketing, and distribution capabilities; a decline in general economic conditions nationally and internationally; the market and size of the vitamin mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to develop pharmaceutical business; our reliance on a limited number of third-party party suppliers for certain raw materials; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; and the risks and uncertainties associated with our business and financial condition in general. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. About Non-GAAP Financial Measures Niagen Bioscience's non-GAAP financial measure, Adjusted EBITDA, is defined as net income before interest, provision for income taxes, depreciation, amortization, non- cash share-based compensation costs, severance and restructuring expense and other infrequent items, including the reversal of previously accrued royalties and license maintenance fees, and the recovery of previously recognized credit losses from a legal settlement. Niagen Bioscience used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for Niagen Bioscience's financial results in accordance with GAAP. Reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is attached to this presentation. FDA Disclaimer Statements made in this presentation have not been evaluated by the Food and Drug Administration. Niagen Bioscience products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors.

------

![](ex992earningspresentatio003.jpg)

• Total company and Tru Niagen® net sales: $34.0 million and $26.0 million, up 33%, and 44% YoY, respectively. • Gross margin: 64.5%, up 100bps YoY. • Sales and marketing expense as a percentage of net sales: 25.8%, an improvement of 170 basis points YoY. • Net income: $4.6 million or $0.06 earnings per share, up $2.7 million and $0.04 YoY. • Adjusted EBITDA(1): $6.4 million, up $3.5 million YoY. • Cash provided from operations: $12.8 million year-to-date, ending with $64.3 million in cash and no debt. • In September, the Company launched AboutNAD®, a digital platform to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging. The site provides consumers, clinicians, and researchers access to synthesized content and peer-reviewed literature on emerging science. • In October, Niagen Bioscience expanded distribution of pharmaceutical-grade Niagen Plus™ IV and injectable therapies to over 1,000 clinics nationwide, including more than 50 iCRYO locations, further scaling its clinical-grade NAD+ delivery network and access to healthcare providers. • Reaffirmed increased full year 2025 outlook: ◦ Net sales growth between 25%-30% (previously 22%-27%) driven by strong momentum in Tru Niagen® and Niagen® ingredients. ◦ Updated general and administrative and research and development expense outlook. Q3 2025 & Recent Highlights (1) See slide 11 for the non-GAAP reconciliation Achieved another quarter of strong revenue and earnings growth, driven by continued operational execution, market leadership in NAD+, and effective cost discipline. 3

------

![](ex992earningspresentatio004.jpg)

Leadership Team Rob Fried Chief Executive Officer E-commerce & entertainment industry executive Savoy Pictures, Columbia Pictures, Fried Films, FeeIn, WHN, Healthspan Research Andrew Shao SVP, Global Regulatory & Scientific Affairs Over two decades of global nutrition industry experience at Amway, Herbalife Nutrition, and the Council for Responsible Nutrition Ozan Pamir Chief Financial Officer Over a decade of capital markets and public company experience in the life sciences industry CFA Charterholder Carlos Lopez SVP, General Counsel Over a decade of experience in the dietary supplements industry. Previously served as VP, General Counsel at The Vitamin Shoppe and board member of The Natural Products Association Michiko Kelley Chief Marketing Officer Over two decades of experience in marketing strategy, marketing operation, product management, and leadership at Dexcom and Sony Electronics 4

------

![](ex992earningspresentatio005.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) Financial Highlights

------

![](ex992earningspresentatio006.jpg)

Q3 2025 Net Sales Mix E-Commerce 58% Watson's & Other B2B 13% Food-grade Niagen® 23% Pharmaceutical-grade Niagen® 3% Analytical Reference Standards & Services 3% Q3 2024 $25.6 MM E-Commerce 56% Watson's & Other B2B 21% Food-grade Niagen® 18% Pharmaceutical-grade Niagen® 2% Analytical Reference Standards & Services 2% Other Ingredients 1% $34.0 MM Q3 2025 • Tru Niagen® net sales totaled 77% of net sales in Q3 2025 compared to 71% in Q3 2024(1) • Niagen®-related net sales remained at 97% of net sales in Q3 2025 compared to Q3 2024(2) Higher mix of Tru Niagen® sales in Q3 2025 compared to the prior year, reflecting sustained E-Commerce momentum and new B2B partnerships. (1) Tru Niagen® net sales include E-Commerce, Watson's & Other B2B (2) Niagen®-related sales include Tru Niagen®, food-grade Niagen® and pharmaceutical-grade Niagen®. 6

------

![](ex992earningspresentatio007.jpg)

Q3 2025 Net Sales Q3 2025 Net Sales ($ in millions) 19.0 7.0 6.4 .5 0.8 0.3 E-Commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients $26.0 YoY % (vs Q3 2024) +29% +109% +11% (2)% +33%Total Growth Rates Total company sales in Q3 2025 up 33% year-over-year. Tru Niagen® related sales continue to grow, driven by increasing demand across the expanding global NAD+ market. 7 N/A (43)%

------

![](ex992earningspresentatio008.jpg)

Year-to-Date 2025 Net Sales YTD 2025 Net Sales ($ in millions) Total YoY % (vs YTD 2024) $70.2 53.9 16.3 19.4 2.9 2.4 0.7 E-Commerce Watson's & Other B2B Food-grade Niagen® Pharmaceutical-grade Niagen® Analytical Reference Standards & Services Other Ingredients Growth Rates 8 +33% 21% +49% +4% +36% N/A Strong total company growth of 36% year-over-year fueled by Tru Niagen® and Niagen® Ingredient sales across our expanding E-commerce and partnership channels. +222%

------

![](ex992earningspresentatio009.jpg)

2024 – 2025 Net Sales Summary 9 ($ in millions) 2025 2024 Description Q1 Q2 Q3 Q1 Q2 Q3 Q4 FY Ecommerce 16.8 18.1 19.0 12.9 13.0 14.8 17.3 58.0 Watsons & Other B2B 4.7 4.6 7.0 4.5 5.6 3.3 5.4 18.8 Total TRU NIAGEN 21.5 22.7 26.0 17.4 18.6 18.1 22.7 76.8 Food-grade NIAGEN 7.0 6.0 6.4 4.1 3.1 5.8 4.5 17.5 Pharmaceutical-grade NIAGEN 1.0 1.4 0.5 0.0 0.0 0.9 0.8 1.7 Total NIAGEN Ingredient 8.0 7.4 6.9 4.1 3.1 6.7 5.3 19.2 NIAGEN Related Revenues 29.5 30.1 32.9 21.5 21.7 24.8 28.0 96.0 Other Ingredients 0.2 0.2 0.3 0.0 0.2 0.0 0.4 0.6 Analytical Reference Standards & Services 0.8 0.8 0.8 0.7 0.8 0.8 0.7 3.0 Total Net Sales 30.5 31.1 34.0 22.2 22.7 25.6 29.1 99.6 TRU NIAGEN as % of Total Net Sales 71 % 73 % 77 % 78 % 82 % 71 % 78 % 77 % NIAGEN Related Revenues as % of Total Net Sales 97 % 97 % 97 % 97 % 96 % 97 % 96 % 96 % YOY Growth Rate - Net Sales Total Company 38 % 37 % 33 % (2) % 12 % 31 % 37 % 19 % NIAGEN Related 37 % 38 % 33 % — % 12 % 32 % 38 % 20 % Total TRU NIAGEN 24 % 22 % 44 % (2) % 10 % 4 % 29 % 10 %

------

![](ex992earningspresentatio010.jpg)

Q3 2025 vs Q3 2024 Key P&L Metrics (in thousands) Q3 2025 Q3 2024 Notes Net Sales $33,986 $25,580 Tru Niagen® business up 44% driven by strong E-commerce performance, paired with modest Niagen® ingredient growth. Gross Profit % of Net Sales 21,928 64.5% 16,240 63.5% Up 100bps primarily driven by changes in product mix, the use of lower-cost inventory purchases, and improvements in labor and overhead utilization rates with higher sales. Sales and Marketing % of Net Sales 8,768 25.8% 7,044 27.5% Improved investments and sales efficiency, driven by strong E-commerce performance. Research and Development 1,795 1,290 Higher R&D expenses in current period, driven by increased professional fees, employee related expenses, and lab supply purchases to support ongoing development activities. General and Administrative 7,129 6,304 Increase due to higher employee-related expenses, share-based compensation, and partially offset by reduction in consulting fees. Total Operating Expense 17,692 14,638 Greater investments in growth and operating functions. Operating Income $4,236 $1,602 Reflects strong net sales growth and gross margins, partially offset by higher operating expense. 10

------

![](ex992earningspresentatio011.jpg)

Adjusted EBITDA Summary Adjusted EBITDA grew to $6.4 million in Q3 2025 from $2.9 million in the prior year quarter, reflecting improved operating efficiency and higher share-based compensation. 11 (1) The reversal of royalties and fees relates to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements. (2) The recovery of credit losses stems from the 2024 legal settlement with Elysium Health, LLC, paid in two installments, reversing a bad debt write-off from 2019. Niagen Bioscience, Inc. and Subsidiaries Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY 2024 Three Months Ended Nine Months Ended September 30, 2025Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Net income (loss), as reported $(492) $(15) $1,878 $7,179 $8,550 $5,063 $3,609 $4,578 $13,250 Adjustments Interest income, net (239) (241) (276) (373) (1,129) (459) (552) (564) (1,575) Provision for income taxes — — — 305 305 168 128 222 518 Depreciation 178 170 164 151 663 158 158 157 473 Amortization of intangibles 38 37 38 38 151 37 38 38 113 Noncash lease expense 174 163 164 169 670 173 159 164 496 Share-based compensation 984 1,185 735 752 3,656 1,075 1,488 1,756 4,319 Severance and restructuring 27 276 185 (4) 484 4 21 10 35 Reversal of previously accrued royalties and license maintenance fees (1) — — — (3,521) (3,521) — — — — Recovery of credit losses related to legal settlement (2) — — — (1,325) (1,325) (1,325) — — (1,325) Adjusted EBITDA $670 $1,575 $2,888 $3,371 $8,504 $4,894 $5,049 $6,361 $16,304

------

![](ex992earningspresentatio012.jpg)

Q3 2025 Operating Income vs Q3 2024 ($ in millions) +$6.2 MM 1.6 5.3 0.3 0.4 0.2 (1.7) (1.0) (0.4) (0.5) 4.2 Q3 2024 Operating Income Volume Gross Margin Improvement Legal Severance and Restructuring Sales & Marketing Equity Comp (G+A) Other G+A Research and Development Q3 2025 Operating Income $0.0 $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $8.0 $9.0 12 -$3.6 MM

------

![](ex992earningspresentatio013.jpg)

Quarterly Balance Sheet Highlights (in thousands) 3/31/24 6/30/24 9/30/24 12/31/24 3/31/25 6/30/25 9/30/25 Key Drivers (Q4 2024 vs Q3 2025) Cash $27,565 $27,885 $32,398 $44,660 $55,616 $60,474 $64,290 Up $19.6 million primarily driven by net income and proceeds from stock option exercises Inventory 12,495 11,511 10,544 9,192 11,185 14,406 18,791 Up $9.6 million as inventory levels continue to scale to meet growing business needs and build-up sufficient reserves Trade Receivables 6,604 7,818 7,096 7,768 7,052 9,656 8,506 Up $0.7 million driven by higher sales and timing of orders and collections, consistent with historic trends and continued efficient collections Accrued Liabilities 10,465 8,621 9,592 7,817 9,050 7,381 8,700 Up $0.9 million driven by changes in and timing of expenses, consistent with historic trends Accounts Payable 7,899 8,105 6,903 8,526 10,632 13,680 12,742 Up $4.2 million driven by increased inventory purchases and timing of disbursements Equity $28,951 $30,718 $34,369 $46,094 $55,345 $64,195 $70,676 Up $24.6 million driven by net income, share-based compensation and proceeds from stock option exercises Consistent balance sheet growth reflects disciplined expansion and scalable operations, supported by positive working capital that sustains profitability. 13

------

![](ex992earningspresentatio014.jpg)

Cash Flow Highlights Three Months Ended FY 2024 Three Months Ended Nine Months Ended September 30, 2025(in thousands) 3/31/24 6/30/24 9/30/24 12/31/24 3/31/25 6/30/25 9/30/25 Net Income (Loss) $(492) $(15) $1,878 $7,179 $8,550 $5,063 $3,609 $4,578 $13,250 Working Capital (643) (1,837) 1,235 5,111 3,866 2,681 (4,399) (3,004) (4,722) Cash From / (Used for) Operations 295 (264) 3,495 8,583 12,109 7,883 1,250 3,692 12,825 Cash Used for Investing (41) (12) (21) (69) (143) (32) (135) (24) (191) Cash From / (Used for) Financing (14) 596 (1) 1,039 (2) 3,748 (3) 5,369 (4) 3,105 (5) 3,743 (6) 148 (7) 6,996 (8) Net Increase in Cash $240 $320 $4,513 $12,262 $17,335 $10,956 $4,858 3,816 $19,630 Ending Cash Balance $27,565 $27,885 $32,398 $44,660 $44,660 $55,616 $60,474 $64,290 $64,290 Strong cash generation for the year driven by earnings growth and stock option exercise proceeds enhanced liquidity, with $64.3 million in cash and no outstanding debt facilities. 14 1. Includes $0.6 million in proceeds from the exercise of stock options. 2. Includes $1.0 million in proceeds from the exercise of stock options. 3. Includes $3.8 million in proceeds from the exercise of stock options. 4. Includes $5.4 million in proceeds from the exercise of stock options 5. Includes $3.1 million in proceeds from the exercise of stock options. 6. Includes $3.7 million in proceeds from the exercise of stock options. 7. Includes $0.2 million in proceeds from the exercise of stock options. 8. Includes $7.0 million in proceeds from the exercise of stock options

------

![](ex992earningspresentatio015.jpg)

2025 Financial Outlook Strong 2025 net sales growth supported by continued investment in brand building, operational scalability, and R&D to drive future innovation and expansion. 15(1) FY 2024 actual G&A includes the reversal of royalties and fees related to a supplemental agreement with Dartmouth, which waived certain obligations under the exclusive license agreements totaling $3.5 million and the recovery of approximately $1.3 million in credit losses related to the legal settlement with Elysium Health, LLC. (in thousands) 2024 Actual 2025 Full Year Outlook Key Drivers Net Sales $99,597 Between 25%-30% growth YoY (Previously between 22%-27% growth YoY) • Includes growth from E-commerce business and recurring revenues from established partnerships. • Includes revenues from new B2B partnerships in the expanding NAD+ market. Gross Margin % (as a % of net sales) 61.8% Improvement YoY (Previously slight improvement YoY) • Continued supply chain optimization and cost savings initiatives. • Includes benefit from lower-cost inventory sales. Sales & Marketing (as a % of net sales) $29,469 Up in absolute dollars and down as a % of net sales YoY (29.6% of net sales in FY 2024) • Strategic investments to drive brand awareness, and increase customer acquisition and retention while enhancing marketing efficiencies. Research & Development $6,016 Up in absolute dollars and down as a % of net sales YoY (6.0% of net sales in FY 2024) (Previously up in absolute dollars and stable as a % of net sales YoY) • Includes investments in external research to support new product development, and continued NAD precursor development. General & Administrative(1) $18,375 Up $8.0 to $9.0 million in absolute dollars YoY (Previously up $7.0 to $8.0 million in absolute dollars YoY) • Increased share-based compensation related to the CEO stock performance award and investments to support strategic business initiatives and business growth, plus the absence of 2024 royalty expense reversals.

------

![](ex992earningspresentatio016.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) 16 The Science

------

![](ex992earningspresentatio017.jpg)

Scientific Advisory Board 17

------

![](ex992earningspresentatio018.jpg)

Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of October 20, 2025. 18

------

![](ex992earningspresentatio019.jpg)

The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019) Contact Info: Niagen Bioscience Investor Relations: ICR, LLC Reed Anderson T: +1 (626) 277-1260 Stephanie Carrington T: +1 (626) 277-1282 NiagenIR@ICRInc.com www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com 19

------